Indication
Gastric Cancer
Aliases
gastric cancer
67 clinical trials
90 products
28 drugs
21 documents
Drug
5-FUClinical trial
A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer(PD-L1 + / MSI-H / EBV +/dMMR)Status: Recruiting, Estimated PCD: 2025-03-31
Product
SerplulimabDrug
DocetaxelDrug
S1Clinical trial
A Phase 1B/2 Study of Trastuzumab, Bevacizumab With Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy (TREAZURE)Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
An Open-label, Multicenter, First-in-human Dose-escalation and Cohort Expansion Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of IMM2902 in the Treatment of HER2-expressing Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-10-01
Product
IMM2902Clinical trial
A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)Status: Recruiting, Estimated PCD: 2028-03-31
Drug
AN0025Drug
fluorouracilDrug
mFOLFOX6Drug
FOLFOXIRIClinical trial
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMMUNE)Status: Recruiting, Estimated PCD: 2027-10-31
Drug
T-VECDrug
TiragolumabProduct
RamucirumabClinical trial
Multicenter Randomized Controlled Trial of Gastric Endoscopic Submucosal Dissection With or Without Epineprhine Added SolutionStatus: Completed, Estimated PCD: 2022-12-31
Product
EpinephrineClinical trial
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Product
BerzosertibDrug
IrinotecanClinical trial
Efficacy and Safety of Neoadjuvant Sintilimab Puls FLOT Versus Sintilimab Puls SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric CancerStatus: Not yet recruiting, Estimated PCD: 2026-07-01
Product
SOX+SintilimabProduct
FLOT+SintilimabClinical trial
A Pilot Study of Pembrolizumab and Lenvatinib Combination Therapy in Patients With Previously Treated Advanced Gastroesophageal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-12-30
Product
LenvatinibProduct
PembrolizumabClinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)Status: Recruiting, Estimated PCD: 2025-02-24
Drug
cyclophosphamideProduct
Neoantigen Peptide VaccineClinical trial
A Phase Ib Trial of Preoperative Short-Course Chemoradiotherapy Followed by Chemotherapy for Resectable Gastric AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2028-12-31
Drug
UTD1Clinical trial
A Phase 2A, Dose-Finding Study of Ad5.F35-hGCC-PADRE Vaccine in Adults With Gastrointestinal Adenocarcinomas at Risk of Relapse Post Definitive Surgery and Standard TherapyStatus: , Estimated PCD: 2024-07-01
Clinical trial
Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 StudyStatus: Recruiting, Estimated PCD: 2024-07-31
Product
Trifluridine and TipiracilClinical trial
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal CancerStatus: Recruiting, Estimated PCD: 2026-12-21
Product
FOLFOXClinical trial
Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma: A Single-center, Single-arm, Phase Ⅱ StudyStatus: Recruiting, Estimated PCD: 2024-07-18
Product
TislelizumabProduct
CAPOXClinical trial
SCAFIGC：Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II TrialStatus: Recruiting, Estimated PCD: 2023-10-01
Product
Paclitaxel±RamucirumabClinical trial
A Pilot Study of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastroesophageal AdenocarcinomaStatus: Completed, Estimated PCD: 2023-01-27
Clinical trial
Phase I Trial of Sonidegib and Pembrolizumab in Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-07-01
Product
SonidegibClinical trial
A Phase I Study of Intraperitoneal Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive CytologyStatus: Active (not recruiting), Estimated PCD: 2028-10-30
Clinical trial
Comparison of With and Without Sequential Single Drug Therapy of S-1 After Adjuvant Chemotherapy With Docetaxel Plus S-1 in Stage III Gastric CancerStatus: Recruiting, Estimated PCD: 2026-12-31
Product
Tegafur-Gimeracil-OteracilClinical trial
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced MalignanciesStatus: Terminated, Estimated PCD: 2023-12-01
Product
SEA-TGTProduct
sasanlimabProduct
Brentuximab vedotinProduct
Brentuximab VedotinClinical trial
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-03-01
Product
IrinotecanProduct
LurbinectedinClinical trial
Intravital Microscopy (IVM) in Human Solid TumorsStatus: Completed, Estimated PCD: 2023-12-31
Product
Fluorescein SodiumClinical trial
Molecular Analysis for Therapy Choice (MATCH)Status: Active (not recruiting), Estimated PCD: 2025-12-31
Drug
AdavosertibProduct
AfatinibProduct
BinimetinibProduct
CapivasertibClinical trial
A Multicenter, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Gastric CarcinomaStatus: Terminated, Estimated PCD: 2022-05-30
Product
BDC-1001Product
NivolumabClinical trial
Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination With Nivolumab in Patients With Advanced HER2-Expressing Solid TumorsStatus: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2021-09-17
Product
OlaparibProduct
MEDI4736Product
BevacizumabProduct
NKT3447Clinical trial
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 3, Multi-Center, Double-Blind, Randomized, Efficacy and Safety Study of M108 Monoclonal Antibody Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.Status: Recruiting, Estimated PCD: 2027-01-11
Product
PlaceboProduct
CapecitabineProduct
M108 monoclonal antibodyProduct
OxaliplatinProduct
MitoxantroneClinical trial
A Phase 2 Study of Futibatinib in Patients With Specific FGFR AberrationsStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Product
FutibatinibClinical trial
Open Label, Non-randomized, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of S095029 (Anti-NKG2A Antibody) as a Part of Combination Therapy in Participants With Locally Advanced and Unresectable or Metastatic MSI-H/dMMR Gastro-esophageal Junction /Gastric CancerStatus: Not yet recruiting, Estimated PCD: 2026-06-10
Product
S095029Clinical trial
A Prospective Non-interventional Study (NIS) of Trastuzumab DeRuxtecan (T-DXd) for Adult Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction (GEJ) AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen, Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies in a Real-world Setting in Europe (PROSPERITY)Status: Recruiting, Estimated PCD: 2026-12-01
Product
Trastuzumab deruxtecanClinical trial
A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid TumoursStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Product
BOLD-100Product
BT5528Clinical trial
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 ExpressionStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved TherapiesStatus: Completed, Estimated PCD: 2022-01-12
Product
A166Clinical trial
Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination With Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors With HER2 ExpressionStatus: Not yet recruiting, Estimated PCD: 2026-03-31
Product
AzenosertibProduct
Trastuzumab DeruxtecanClinical trial
Effect of Helicobacter Pylori Eradication on Glandular Atrophy and Metachronous Cancer in Patients Undergoing Endoscopic Mucosal Resection for Gastric CancerStatus: Active (not recruiting), Estimated PCD: 2016-06-01
Product
OmeprazoleClinical trial
A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) CancerStatus: Recruiting, Estimated PCD: 2027-10-31
Drug
AtezolizumabProduct
LeucovorinClinical trial
Phase 1b/2 Clinical Trial of Neoadjuvant Pembrolizumab Plus Concurrent Chemoradiotherapy With Weekly Carboplatin and Paclitaxel in Adult Patients With Resectable, Locally Advanced Adenocarcinoma of the Gastroesophageal Junction or Gastric CardiaStatus: Completed, Estimated PCD: 2021-07-01
Product
CarboplatinProduct
FluorouracilClinical trial
Phase I/Ib Trial of ATR Inhibitor BAY 1895344 in Combination With FOLFIRI in GI Malignancies With a Focus on Metastatic Colorectal and Gastric/Gastroesophageal CancersStatus: Active (not recruiting), Estimated PCD: 2024-03-29
Product
ElimusertibProduct
PaclitaxelProduct
Leucovorin CalciumClinical trial
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage ResponseStatus: Recruiting, Estimated PCD: 2024-12-01
Product
TalazoparibClinical trial
Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor TreatmentStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Product
TrametinibClinical trial
A Phase II Study of agenT-797 (Invariant Natural Killer T Cells), Botensilimab, a Novel Fc-enhanced CTLA-4 Inhibitor, Plus Balstilimab (Anti-PD-1) With Ramucirumab and Paclitaxel for Patients With Previously Treated, Advanced Esophageal, Gastric, or Gastro-esophageal Junction AdenocarcinomaStatus: Recruiting, Estimated PCD: 2027-08-01
Product
AgenT-797Drug
BotensilimabProduct
BalstilimabClinical trial
XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study ( FISSION Study )Status: Recruiting, Estimated PCD: 2025-11-25
Clinical trial
COordinated Nivolumab and IntraperiToneal IL-2 for Gastric CanceR With PeritOneaL Metastasis (CONTROL) Phase 1b Pilot StudyStatus: Recruiting, Estimated PCD: 2026-01-01
Product
AldesleukinClinical trial
Disitamab Vedotin Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer With HER2 Overexpression: a Prospective, Phase II StudyStatus: Not yet recruiting, Estimated PCD: 2027-05-01
Drug
RC48Drug
AdebrelimabProduct
ApatinibDrug
S-1Clinical trial
A Randomized Trial Comparing Early Local Chemoradiation Therapy +/- Surgery Versus Systemic Therapy for Patients With Esophageal or Gastric Cancer With OligometastasesStatus: Recruiting, Estimated PCD: 2026-12-31
Drug
CisplatinClinical trial
A Phase II Clinical Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ CancerStatus: Recruiting, Estimated PCD: 2024-11-20
Clinical trial
The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer: A Multicenter Real-world Clinical StudyStatus: Active (not recruiting), Estimated PCD: 2022-12-30
Clinical trial
Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.Status: Active (not recruiting), Estimated PCD: 2025-11-01
Clinical trial
Circulating Tumor DNA Minimal Residual Disease-guided Adjuvant Chemotherapy in Patients With Stage II-III Gastric CancerStatus: Recruiting, Estimated PCD: 2027-04-01
Product
MRD-guided therapyClinical trial
Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer: A Multicenter, Phase II StudyStatus: Completed, Estimated PCD: 2022-02-28
Clinical trial
Total Neoadjuvant Chemotherapy With 5-fluoruracil, Leucovorin, Oxaliplatin and Docetaxel in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR): Randomized, Single Center, Open Label Trial, Phase 2/3Status: Recruiting, Estimated PCD: 2027-12-01
Drug
TrastuzumabClinical trial
Pilot Study of Dual Checkpoint Inhibition Followed by Immuno-Chemoradiation in Patients With Resectable Gastric Adenocarcinoma (Concept ID 2016-NIV-0551)Status: Active (not recruiting), Estimated PCD: 2026-12-30
Clinical trial
Phase 2 Study of Epacadostat (INCB024360) With Pembrolizumab (MK3475) in Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma Requiring Paired BiopsiesStatus: Completed, Estimated PCD: 2018-05-29
Product
EpacadostatClinical trial
An Open Label, Single-arm, Multi-center Phase 1b/2 Combination Study of M7824 (Bintrafusp Alfa) and Paclitaxel in Recurrent/Metastatic Gastric Cancer as a Second-line TreatmentStatus: Completed, Estimated PCD: 2023-10-27
Product
M7824+paclitaxelClinical trial
A Phase II Study of Preoperative Pembrolizumab for Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Followed by Chemotherapy and Chemoradiation With PembrolizumabStatus: Recruiting, Estimated PCD: 2023-12-31
Drug
LurbinectedinClinical trial
Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2028-11-08
Drug
mFOLFOXIRIClinical trial
A Single Arm, Phase ll Exploratory Clinical Study of Pemetinib in the Treatment of Advanced Gastric Cancer With FGFR Mutation and Previous Standard Treatment FailureStatus: Not yet recruiting, Estimated PCD: 2024-12-30
Product
PemigatinibClinical trial
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Drug
olaparibClinical trial
Randomized Clinical Trial:Clinical Study of Weifuchun Treatment on Gastric CancerStatus: Completed, Estimated PCD: 2020-10-01
Product
WeifuchunClinical trial
Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)Status: Recruiting, Estimated PCD: 2026-03-31
Drug
CeralasertibClinical trial
Randomized Clinical Trial:Clinical Study of Modified Banxia Xiexin Decoction Treatment on Gastric CancerStatus: Completed, Estimated PCD: 2022-12-01
Product
Banxia Xiexin DecoctionClinical trial
A Phase I and Randomized Phase II Double Blinded Placebo Controlled Study of mFOLFOX6 +/- AMG 337 in the First Line Treatment of Patients With Her2/Neu Negative and High MET Expressing Advanced Gastric and Esophageal AdenocarcinomaStatus: , Estimated PCD: 2015-03-06
Product
AMG 337Drug
oxaliplatinClinical trial
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal MalignanciesStatus: Completed, Estimated PCD: 2017-12-01
Clinical trial
PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-06-08
Clinical trial
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Intraperitoneal Bevacizumab in Gastric Cancer With Peritoneal MetastasisStatus: , Estimated PCD: 2025-03-01
Product
Albumin-bound paclitaxelDrug
sintilimabDrug
afatinibDocument
DailyMed Label: CapecitabineDocument
DailyMed Label: OntruzantDocument
DailyMed Label: HERZUMADocument
DailyMed Label: XelodaDocument
DailyMed Label: TrazimeraDocument
DailyMed Label: CYRAMZADocument
DailyMed Label: KanjintiDocument
DailyMed Label: LONSURFDocument
DailyMed Label: OPDIVODocument
DailyMed Label: OGIVRIDocument
DailyMed Label: DocetaxelDocument
DailyMed Label: EnhertuDocument
DailyMed Label: KEYTRUDADocument
DailyMed Label: AdriamycinDocument
DailyMed Label: DOCIVYXDocument
DailyMed Label: capecitabine
Document
DailyMed Label: HerceptinDocument
DailyMed Label: MetoclopramideProduct
ChemotherapyProduct
Trastuzumab EmtansineProduct
Docetaxel anhydrousProduct
trastuzumab-qyypProduct
KanjintiProduct
OGIVRIProduct
TaxotereProduct
DoxorubicinProduct
doxorubicinProduct
MetoclopramideProduct
metoclopramide hydrochlorideDocument
DailyMed Label: MITOMYCINProduct
Mitomycin